Kelun tests whether KL0011034 interacts with the anesthetic alfentanil
A 27-subject Phase 1 study will check if Kelun's injectable KL0011034 alters alfentanil exposure or sedation depth in chronic pain patients before broader dosing decisions proceed.
Executive Summary
- Hunan Kelun Pharmaceutical has registered a Phase 1 study testing whether its investigational injectable interacts with a standard anesthetic when given together to chronic pain patients.
- The primary measure is adverse events, with secondary measures tracking sedation depth, consciousness, and how each drug's blood levels shift when combined, the profile of a pharmacokinetic and safety interaction study rather than an efficacy trial.
- No competitor trial shares KL0011034's target or mechanism in the supplied competitive field; the nearest comparable programs are established opioid and cannabinoid-pathway analgesics tested against the same non-cancerous chronic pain indication, and none of them tests this drug-drug interaction question.
- The study has not yet begun recruiting, and its outcome will shape whether KL0011034 can be dosed around procedures that require this anesthetic, a gating question for any broader development plan.
The trial
The study, listed under NCT07710560, will test KL0011034 Injection alongside Alfentanil Hydrochloride Injection in adults aged 18 to 55 with moderate-to-severe non-cancerous chronic pain, defined by a pain score of at least 4 on the numeric rating scale. It is designed with 3 arms and an open-label format, meaning all participants and investigators know which treatment is given. The sponsor anticipates enrolling 27 subjects, and the study has not yet started recruiting as of its registration. NCT07710560A Study Evaluating the Drug-Drug Interaction Between KL0011034 Injection and Alfentanil Hydrochloride InjectionNCT07710560
What it measures
The primary endpoint counts the number of reported adverse events in the 24 hours following each dose, the standard measure for a safety-focused interaction study. Secondary measures track pharmacokinetic parameters, including peak plasma concentration, half-life, and total drug exposure, for both KL0011034 and alfentanil when given alone versus combined. The design also monitors sedation depth directly: bispectral index (BIS) electroencephalogram readings, loss of the eyelash reflex, and the Modified Observer's Assessment of Alertness and Sedation scale, tools clinicians use to gauge how deeply a patient is sedated during anesthesia. Discharge readiness is separately tracked with the Modified Aldrete recovery scale. NCT07710560A Study Evaluating the Drug-Drug Interaction Between KL0011034 Injection and Alfentanil Hydrochloride InjectionNCT07710560
Why the interaction question matters
Combining an investigational analgesic with alfentanil, an opioid anesthetic used for procedural sedation, carries a real pharmacological question: whether KL0011034 changes alfentanil's blood levels or independently deepens sedation, which would affect how the two could be dosed together outside a controlled setting. The trial's exclusion criteria bar volunteers with any history of anesthesia complications, difficult airways, or respiratory conditions such as sleep apnea, underscoring that respiratory and sedation safety is the central concern the study is built to catch. NCT07710560A Study Evaluating the Drug-Drug Interaction Between KL0011034 Injection and Alfentanil Hydrochloride InjectionNCT07710560
The competitive field
KL0011034's molecular target is not established in the supplied competitive data, so no isolation or first-in-class claim follows from that gap alone. What is established is the field around it: the nearest programs tested in non-cancerous chronic pain are established opioid analgesics, including MedtronicNeuro's work with morphine, Mundipharma's oxycodone, Mallinckrodt's hydromorphone, and Endo's oxymorphone, alongside Eli Lilly's fepixnebart, an NGF-targeting antibody in Phase 2. None of these shares KL0011034's drug-drug interaction design; they test the analgesics themselves, not a combination with an anesthetic. That leaves KL0011034's interaction question without a direct trial-design precedent in the supplied set, a study built to answer a procedural-safety question the efficacy trials in the field do not address.
Sponsor context
Hunan Kelun Pharmaceutical currently runs 7 trials across its pipeline, with 4 recruiting, 2 completed, and this study among 1 not yet recruiting. KL0011034 has no other trial on record besides this one.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.